Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

BACKGROUND: In this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from metastatic non-small cell lung cancer (mNSCLC). METHODS: Patients with lung or liver lesions amenable to RT plus at least on...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsh, James, Menon, Hari, Chen, Dawei, Verma, Vivek, Tang, Chad, Altan, Mehmet, Hess, Kenneth, de Groot, Patricia, Nguyen, Quynh-Nhu, Varghese, Rejani, Comeaux, Nathan I, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y, Papdimitrakopoulou, Vasiliki, Lin, Steven H, Heymach, John V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555111/
https://www.ncbi.nlm.nih.gov/pubmed/33051340
http://dx.doi.org/10.1136/jitc-2020-001001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555111/
https://www.ncbi.nlm.nih.gov/pubmed/33051340
http://dx.doi.org/10.1136/jitc-2020-001001

Ejemplares similares